Voyager Therapeutics (VYGR) Income towards Parent Company (2014 - 2026)

Voyager Therapeutics has disclosed Income towards Parent Company across 13 years of filings, most recently posting -$27.9 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$27.9 million, up 9.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$116.6 million (down 37.72% YoY), and the FY2025 annual result was -$119.7 million, down 84.18% from the prior year.
• Income towards Parent Company came in at -$27.9 million for Q1 2026 at Voyager Therapeutics, down from -$27.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $124.0 million in Q1 2023 to a low of -$34.5 million in Q4 2024.
• The 5-year median for Income towards Parent Company is -$22.2 million (2023), against an average of -$7.5 million.
• Across the five-year window, Income towards Parent Company tumbled 566.69% in 2022 and soared 681.85% in 2023, its largest moves.
• Voyager Therapeutics' Income towards Parent Company stood at -$23.6 million in 2022, then soared by 338.86% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then gained by 20.47% to -$27.4 million in 2025, then dropped by 1.86% to -$27.9 million in 2026.
• The last three Income towards Parent Company figures came in at -$27.9 million (Q1 2026), -$27.4 million (Q4 2025), and -$27.9 million (Q3 2025), per Business Quant data.